Toxin-Specific Antibodies for Clostridium difficile Treatment
Author Information
Author(s): Hussack Greg, Tanha Jamshid
Primary Institution: Institute for Biological Sciences, National Research Council of Canada
Hypothesis
Can toxin-specific antibodies effectively treat Clostridium difficile-associated disease (CDAD)?
Conclusion
Toxin-specific antibodies have shown promise in treating CDAD and preventing disease relapse.
Supporting Evidence
- Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans.
- Patients with low anti-toxin IgG titers are more likely to experience severe effects from C. difficile infection.
- Experimental vaccines have protected animals against C. difficile challenge.
- Oral administration of bovine immunoglobulin G concentrate has shown protective effects in hamsters.
Takeaway
Scientists are exploring special antibodies that can help fight a nasty germ called Clostridium difficile, which makes people very sick. These antibodies can stop the germ's harmful effects and help people feel better.
Methodology
This review summarizes various antibody formats and strategies under development for CDAD immunotherapy.
Limitations
The variability in antibody preparations and the lack of uniform study designs in human trials may affect the comparability of results.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website